This feature is a deep dive into the challenges of defining and treating Difficult-to-Treat Rheumatoid Arthritis (D2T-RA).

Wells Fargo raised the firm’s price target on AnaptysBio (ANAB) to $51 from $40 and keeps an Overweight rating on the shares. The firm believes ...

Think rheumatoid arthritis only affects the elderly? Or that exercise makes it worse? Time to bust these myths! We got in ...

Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe ...

AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

The following is a summary of “A predictive model based on the gut microbiota improves the diagnostic effect in patients with ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Bristol Myers Squibb Co. has patented new protein-arginine deiminase type-4 (PADI4; PAD4) inhibitors reported to be useful for the treatment of rheumatoid arthritis, among others.

Waterloo Road legend Adam Thomas has spoken about his ‘hope’ for the future after a lifestyle change has helped him battle an autoimmune disease. The 36-year-old soap star revealed he had been ...

Protein disulfide isomerases (PDIs) are essential enzymes that facilitate the proper folding of proteins and maintain protein quality within the endoplasmic reticulum.

Rheumatoid arthritis (RA) is an inflammatory arthritis characterized by chronic joint inflammation, cartilage degradation, and bone erosion.